Nucleoside News and Research

RSS

Abbott releases details on phase 3 hepatitis C registrational program

Abbott today released details on its phase 3 hepatitis C registrational program following promising results from its phase 2b clinical trial, known as Aviator, presented at the Annual Meeting of the American Association for the Study of Liver Disease (AASLD) in Boston.

13 Nov 2012

Sapacitabine tolerated, efficacious in elderly leukemia patients

The nucleoside analog sapacitabine appears to be “active and tolerable” in elderly patients with acute myeloid leukemia, say authors of a phase II study reported in the Lancet Oncology.

5 Nov 2012

BioCryst announces withdrawal of BCX5191 IND following discussion with FDA

BioCryst Pharmaceuticals, Inc. announced the withdrawal of its Investigational New Drug application (IND) for the antiviral nucleoside, BCX5191, following a discussion with the U.S. Food and Drug Administration (FDA).

31 Oct 2012

Medivir’s simeprevir and TMC647055 to enter phase IIa combination trial for HCV genotype-1

Medivir AB, announced today that simeprevir (TMC435) and TMC647055, a non-nucleoside inhibitor (NNI) will enter a phase IIa interferon free combination trial.

21 Sep 2012

Study: 172K polymorphism makes certain forms of HIV less resistant to drugs

The human immunodeficiency virus (HIV) can contain dozens of different mutations, called polymorphisms. In a recent study an international team of researchers, including MU scientists, found that one of those mutations, called 172K, made certain forms of the virus more susceptible to treatment. Soon, doctors will be able to use this knowledge to improve the drug regiment they prescribe to HIV-infected individuals.

14 Sep 2012

Medivir strengthens hepatitis C platform

Medivir AB, announced today that it has acquired preclinical research stage assets from Novadex Pharmaceuticals AB. The acquisition includes intellectual property and prodrug technologies in order to further strengthen Medivir's hepatitis C platform and know how.

5 Sep 2012

Rexahn announces completion of RX-3117 exploratory Phase I clinical trial in cancer patients

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that it has completed its exploratory Phase I clinical trial of RX-3117 in cancer patients.

6 Aug 2012

Novel integrase inhibitor dolutegravir shows promise for HIV-1 treatment

The once-daily integrase inhibitor dolutegravir has shown promise in a phase III noninferiority study comparing it with twice-daily raltegravir for treatment of HIV-1, indicate study results presented at the 19th International AIDS Conference in Washington DC, USA.

3 Aug 2012

ART resistance increasing in sub-Saharan Africa

The prevalence of antiretroviral drug resistance is on the rise in sub-Saharan Africa, an increase driven by resistance to non-nucleoside reverse transcriptase inhibitors in east and southern Africa, research shows.

1 Aug 2012

Merck signs two licensing agreements for investigational HIV drug candidates

Merck, known as MSD outside the United States and Canada, announced today that the company has signed two licensing agreements for investigational HIV drug candidates.

25 Jul 2012

Merck, Chimerix sign license agreement for CMX157 to treat HIV infection

Chimerix, Inc. today announced the execution of a license agreement granting Merck, known as MSD outside the United States and Canada, exclusive worldwide rights to CMX157, Chimerix's novel lipid acyclic nucleoside phosphonate currently being evaluated to treat HIV infection.

24 Jul 2012

BD youth show altered frontal lobe bioenergetic metabolism

Results from a US study suggest that depressed unmedicated adolescents with bipolar disorder (BD) have altered frontal lobe mitochondrial function.

24 Jul 2012

HIV drug resistance rates rising in some parts of Africa

New research published Online First in The Lancet suggests that drug-resistant HIV has been increasing in parts of Sub-Saharan Africa since the roll-out of antiretroviral therapy (ART) nearly a decade ago.

23 Jul 2012

All adult patients with HIV should be offered ART: International Antiviral Society-USA panel

Included in the 2012 International Antiviral Society-USA panel recommendations for human immunodeficiency virus (HIV) patient care is that all adult patients, regardless of CD4 cell count, should be offered antiretroviral therapy (ART), according to an article in the July 25 issue of JAMA, a theme issue on HIV/AIDS.

23 Jul 2012

Researchers identify high ARV drug exposure in hair samples of HIV uninfected infants

Researchers from the University of California, San Francisco (UCSF) and Makerere University in Uganda have used hair and blood samples from three-month old infants born to HIV-positive mothers to measure the uninfected babies' exposure—both in the womb and from breast-feeding—to antiretroviral medications their mothers were taking. The results, they said, are surprising.

23 Jul 2012

HIV therapy affects bone mass within 2 years

Young men receiving antiretroviral therapy for recently diagnosed HIV are more likely to have low bone mineral density than are other men of a similar age, US researchers report.

25 Jun 2012

Breckenridge finalizes agreement with Huahai to market Nevirapine Tablets

Breckenridge Pharmaceutical, Inc. announced today that it has finalized its agreement with Zhejiang Huahai Pharmaceuticals Co., Ltd. (Huahai) to market Nevirapine Tablets. Nevirapine 200mg Tablets are AB rated to Viramune a non-nucleoside reverse transcriptase inhibitor (NNRTI) used to treat HIV-1 infection and AIDS, which is marketed by Boehringer Ingelheim.

5 May 2012

Array BioPharma third quarter revenue increases to $19.1M

Array BioPharma Inc. today reported financial results for the third quarter of fiscal 2012.

2 May 2012

New data shows consolidation of interferon-free revolution in HCV treatment

New data presented at the International Liver Congress 2012 shows consolidation of the interferon-free (IFN) revolution in HCV treatment. The much anticipated data from a number of clinical trials confirm that combinations of antivirals offer the hope of shorter, more effective treatment with fewer side effects.

20 Apr 2012

No added HIV risk with hormonal contraceptives

An HIV prevention trial that pre-dates the shift to antiretroviral (ARV)-based approaches is nonetheless helping to answer some of the most relevant and topical questions the field is facing today.

18 Apr 2012